NOVO NORDISK A/S (NYSE: NVO)

NOVO NORDISK A/S

NYSE: NVO (Novo Nordisk A/S)

最近更新时间: 17 Jul, 6:46AM

67.04

-0.18 (-0.27%)

加入群组

前收盘价格	67.22
收盘价格	67.34
成交量	5,296,658
平均成交量 (3个月)	10,009,905
市值	299,820,318,720

市盈率 (P/E TTM)	18.22
预期市盈率 (P/E Forward)	16.69
价格/销量 (P/S)	6.44
股市价格/股市净资产 (P/B)	14.05

52周波幅	57.00 (-14%) — 142.23 (112%)
利润日期	6 Aug 2025
股息率 (DY TTM)	2.40%

市场趋势

		短期	中期
行业	Drug Manufacturers - General (US)	看跌	混合的
	Drug Manufacturers - General (全球的)	看跌	混合的
股票	Novo Nordisk A/S	看跌	看跌

AIStockmoo 评分

-0.4

分析师共识	-2.0
内部交易活动	NA
价格波动	4.5
技术平均移动指标	0.0
技术振荡指标	-4.0
平均	-0.38

相关股票

股票	市值	DY	P/E（TTM）	P/B
NVO	300 B	2.40%	18.22	14.05
LLY	723 B	0.51%	65.48	43.95
NVS	244 B	3.23%	19.11	5.36
MRK	210 B	2.86%	12.17	4.12
JNJ	405 B	2.21%	18.00	5.21
ABBV	335 B	3.36%	81.10	229.94

With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
部门	Healthcare
行业	Drug Manufacturers - General
投资方式	Large Growth
内部持股比例	0.01%
机构持股比例	9.85%

所有权

姓名	日期	持有股份
Fayez Sarofim & Co	31 Mar 2025	11,212,499
Folketrygdfondet	31 Mar 2025	9,521,912
Everett Harris & Co /Ca/	31 Mar 2025	6,408,022

该时间范围内无数据。

日期	类型	细节
29 Jul 2025	公告	Novo Nordisk lowers sales and operating profit outlook for 2025
29 Jul 2025	公告	Maziar Mike Doustdar appointed as president and chief executive officer of Novo Nordisk
25 Jul 2025	公告	European regulatory authority adopts positive opinion for Novo Nordisk’s Alhemo® (concizumab), recommending label expansion to treat haemophilia A and B without inhibitors
21 Jul 2025	CNBC	Weight loss drugs could be a gamechanger for women with a common hormonal disorder
09 Jul 2025	CNBC	Hims & Hers to offer generic semaglutide in Canada as Novo Nordisk patent lapses
28 Jun 2025	公告	HIMS INVESTOR NOTICE: Hims & Hers Health, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
26 Jun 2025	公告	Novo Nordisk continues efforts to support patient access to authentic, FDA approved Wegovy® and prioritize patient safety
23 Jun 2025	公告	Novo Nordisk terminates collaboration with Hims & Hers Health, Inc. due to concerns about their illegal mass compounding and deceptive marketing
23 Jun 2025	公告	Novo Nordisk A/S: Ozempic® receives EU recommendation in peripheral arterial disease, cementing the broad benefits of semaglutide for people with type 2 diabetes and comorbidities
23 Jun 2025	CNBC	Novo Nordisk ends deal with Hims & Hers over sales of Wegovy copycats; HIMS drops 34%
22 Jun 2025	公告	Novo Nordisk A/S: Mim8 prophylaxis treatment shown to be well-tolerated when switching from emicizumab in people with haemophilia A in new phase 3 data presented at the ISTH 2025 Congress
22 Jun 2025	公告	Novo Nordisk A/S: CagriSema 2.4 mg / 2.4 mg demonstrated 22.7% mean weight reduction in adults with overweight or obesity in REDEFINE 1, published in New England Journal of Medicine
20 Jun 2025	公告	Novo Nordisk: Higher dose of Wegovy® provided average weight loss of 21% in people with obesity – with a third achieving 25% or more – according to data presented at ADA
20 Jun 2025	公告	Novo Nordisk’s subcutaneous and oral amycretin data published in The Lancet and presented at ADA 2025
12 Jun 2025	公告	Novo Nordisk to advance subcutaneous and oral amycretin for weight management into phase 3 clinical development
11 Jun 2025	公告	Lexaria's DehydraTECH-Liraglutide Human GLP-1 Clinical Study Supports Pathway to Potential FDA Registration as an Orally-Delivered Capsule
10 Jun 2025	公告	ADA 2025: Novo Nordisk highlights strong portfolio data with new semaglutide and CagriSema results, redefining possibilities in obesity and diabetes care
22 May 2025	公告	New Novo Nordisk initiatives support patient access to authentic, FDA-approved Wegovy® as federal ban on mass compounding of "semaglutide" takes effect
21 May 2025	CNBC	Cigna announces new deal for copay caps on Eli Lilly and Novo Nordisk weight loss drugs
20 May 2025	公告	From Retina Scans to Cancer Trials, AI Is Taking Over the Exam Room
19 May 2025	CNBC	Novo Nordisk is betting on a CEO shake-up to regain its weight loss drug edge over Eli Lilly
16 May 2025	公告	Novo Nordisk A/S: Lars Fruergaard Jørgensen to step down as CEO of Novo Nordisk
14 May 2025	公告	Novo Nordisk A/S: Septerna and Novo Nordisk to collaborate on oral small molecule medicines for obesity and other cardiometabolic diseases
12 May 2025	公告	Novo Nordisk A/S: Once-weekly Sogroya® (somapacitan) is an efficacious and well-tolerated long-acting growth hormone in children with growth disorders: results from REAL8 phase 3 basket study presented at the joint Congress of ESPE and ESE
09 May 2025	公告	Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
07 May 2025	公告	Novo Nordisk's sales increased by 19% in Danish kroner and by 18% at constant exchange rates to DKK 78.1 billion in the first three months of 2025
01 May 2025	CNBC	CVS to boost access to Novo Nordisk's weight loss treatment Wegovy for patients on its drug plans
显示更多

股息率 (DY TTM)	2.40%
5年平均股息收益率	2.48%
股息支付比率	47.09%
预计下次股息支付	Apr 2026

除息日	公告日期	支付日期	详情
31 Mar 2025	05 Feb 2025	08 Apr 2025	1.099206 现金
16 Aug 2024	06 Aug 2024	26 Aug 2024	0.5126402 现金
22 Mar 2024	31 Jan 2024	02 Apr 2024	0.92985 现金
18 Aug 2023	10 Aug 2023	29 Aug 2023	0.8835613 现金
24 Mar 2023	02 Feb 2023	04 Apr 2023	1.1887415 现金
12 Aug 2022	04 Aug 2022	23 Aug 2022	0.5835507 现金
25 Mar 2022	02 Mar 2022	05 Apr 2022	1.022423 现金
16 Aug 2021	-	25 Aug 2021	0.5502889 现金
26 Mar 2021	-	07 Apr 2021	0.922122 现金
14 Aug 2020	06 Aug 2020	25 Aug 2020	0.5177774 现金
27 Mar 2020	06 Feb 2020	07 Apr 2020	0.7826048 现金
16 Aug 2019	10 Aug 2019	27 Aug 2019	0.449438 现金
22 Mar 2019	05 Feb 2019	02 Apr 2019	0.777006 现金
17 Aug 2018	09 Aug 2018	28 Aug 2018	0.462327 现金
23 Mar 2018	24 Mar 2018	03 Apr 2018	0.805982 现金
17 Aug 2017	-	29 Aug 2017	0.33589 现金
23 Mar 2017	-	04 Apr 2017	0.479369 现金
11 Aug 2016	-	23 Aug 2016	0.331026 现金
18 Mar 2016	-	30 Mar 2016	0.69943 现金
19 Mar 2015	-	31 Mar 2015	0.532885 现金
21 Mar 2014	-	02 Apr 2014	0.606122 现金
21 Mar 2013	-	02 Apr 2013	2.264307 现金
22 Mar 2012	-	03 Apr 2012	1.831902 现金
24 Mar 2011	-	05 Apr 2011	1.357901 现金
25 Mar 2010	-	07 Apr 2010	0.978615 现金
19 Mar 2009	-	31 Mar 2009	0.781532 现金
13 Mar 2008	-	25 Mar 2008	0.678462 现金
08 Mar 2007	-	20 Mar 2007	0.891779 现金
09 Mar 2006	-	21 Mar 2006	0.691753 现金
10 Mar 2005	-	22 Mar 2005	0.61725 现金
17 Mar 2004	-	29 Mar 2004	0.52096 现金
26 Mar 2003	-	07 Apr 2003	0.37647 现金
13 Mar 2002	-	25 Mar 2002	0.2848 现金
21 Mar 2001	-	02 Apr 2001	0.5681 现金
24 Mar 2000	-	06 Apr 2000	0.4672 现金
25 Mar 1999	-	06 Apr 1999	0.4182 现金
27 Mar 1998	-	08 Apr 1998	0.3051 现金
25 Apr 1997	-	07 May 1997	0.239 现金
01 May 1996	-	14 May 1996	0.1806 现金
显示更多

每年股息收益率

年份	每年总股息 ($)	频率/年份	收益率 %
2025	1.10	1	1.64
2024	1.44	2	1.68
2023	2.07	2	2.00
2022	1.61	2	2.37
2021	1.47	2	2.63
2020	1.30	2	3.72
2019	1.23	2	4.24
2018	1.27	2	5.51
2017	0.815	2	3.04
2016	1.03	2	5.75
2015	0.533	1	1.84
2014	0.606	1	2.86
2013	2.26	1	12.26
2012	1.83	1	11.22
2011	1.36	1	11.78
2010	0.979	1	8.69
2009	0.782	1	12.24
2008	0.678	1	13.20
2007	0.892	1	13.75
2006	0.692	1	16.54
2005	0.617	1	21.94
2004	0.521	1	19.20
2003	0.376	1	18.38
2002	0.285	1	19.71
2001	0.568	1	28.33
2000	0.467	1	26.40
1999	0.418	1	32.36
1998	0.305	1	22.94
1997	0.239	1	16.57
1996	0.181	1	19.32
显示更多

支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。

投资组合

请登录以添加到您的群组

AI 建议策略模板

自定义的价格提醒

开始购买价格 (EP)

第一个目标价格赚取利润 (TP1)

第二个目标价格赚取利润 (TP2)

停止损失价格 (SL)

请登录以添加到您的群组

已实现利润	-
未实现利润	-
收到股息 2025	-
利润总额	-
平均回报	-
数量(购买)	-
平均价格(购买)	-
数量(卖出)	-
平均价格(卖出)	-

请登录以添加到您的群组

没有符合您标准的股票

营业毛利率	34.51%
营业利益率 (TTM)	49.68%
稀释每股收益 (EPS TTM)	3.67
季度收入增长率 (YOY)	19.50%
季度盈利增长率 (YOY)	14.30%

总债务/股东权益 (D/E MRQ)	85.70%
流动比率 (MRQ)	0.740
营业现金流 (OCF TTM)	131.24 B
杠杆自由现金流 (LFCF TTM)	77.73 B

资产报酬率 (ROA TTM)	23.29%
股东权益报酬率 (ROE TTM)	88.12%

安全边际 (EP)
部分利润 (TP1)
目标利润 (TP2)
最大损失 (SL)